VCA Stocks

IRX Therapeutics, Inc. a privately-held company dedicated to the discovery and development of proprietary drugs for the treatment of cancer and viral diseases, today announced that it has raised $25 million through a Series A Preferred Stock offering.  The Company’s product platform seeks to restore an effective cellular immune response for the treatment of advanced cancers and viral diseases by correcting both dendritic cell and T-cell defects. An effective immune response is essential for the eradication of viruses and tumors.  The Company’s lead product, IRX-2 (citoplurikin), received Fast Track designation by the Food and Drug Administration. Phase 1/2 and Phase 2 clinical trials in late-stage head and neck cancer patients have been completed.